Institut Curie Selects Raystation For Proton Planning


(MENAFN- PR Newswire)

STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Institut Curie, spread over three radiotherapy centers, located in Paris, Orsay, and Saint-Cloud, France, has placed an order for the treatment planning system RayStation®*. Institut Curie is part of the French hospital Network Unicancer, and the order was placed under the Unicancer 2019 Framework agreement.

RayStation will mainly support the Institut Curie Proton Therapy Center in Orsay, which is one of three proton centers in France, all of which are now equipped with RayStation.

The purchase will give Institut Curie access to advanced RayStation technology such as LET optimization, adaptive planning and AI autocontouring capabilities, for both proton and photon treatment planning.

Régis Ferrand, Head of Physics, Institut Curie, says: "Advanced key tools available in the RaySearch environment will help us bring our proton treatments to the highest quality."

Johan Löf, founder and CEO, RaySearch, says: "We are proud of our collaboration with Institut Curie, a well-reputed hospital with an impressive legacy. The agreement is a first step; I look forward to deepening our relationship and to a fruitful collaboration."

The total order value is about 1.7 MEUR excluding service agreement, of which the majority has been recognized as revenue in the third quarter of 2024.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
[email protected]

Learn more about us on:

LinkedIn
YouTube
X

This information was brought to you by Cision

,c4062744

The following files are available for download:

RaySearch Press Release November 7, 2024

,c3349663

Press-release 1200x620 InstCurie

SOURCE RaySearch Laboratories

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN07112024003732001241ID1108860282


PR Newswire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.